Empagliflozin is a medicine used to treat type 2 diabetes that helps lower blood sugar levels by inhibiting the reabsorption of glucose by the kidneys.
Empagliflozin CAS#864070-44-0
Empagliflozin is a medicine used to treat type 2 diabetes that helps lower blood sugar levels by inhibiting the reabsorption of glucose by the kidneys.
Empagliflozin is a white to off-white crystalline powder that is primarily used to treat type 2 diabetes. It belongs to the SGLT2 inhibitor class of drugs that effectively lower blood sugar levels through a specific mechanism and provide additional health benefits while managing diabetes. The main mechanism of action of empagliflozin is to inhibit the reabsorption of glucose by the renal tubules. Normally, the kidneys reabsorb glucose from the blood back into the body through the renal tubules to maintain normal blood sugar levels. However, in patients with type 2 diabetes, this process is often dysregulated, leading to elevated blood sugar levels. Empagliflozin lowers the renal glucose threshold by blocking the action of SGLT2 (sodium-glucose co-transporter 2), prompting glucose to be excreted from the body through urine. This process not only lowers blood sugar levels, but also alleviates the symptoms of diabetes. Empagliflozin performs well in lowering blood sugar and can effectively control blood sugar levels in patients with type 2 diabetes.
In addition to its main glucose-lowering effect, empagliflozin has other significant additional benefits. First, it helps lose weight. By increasing urinary glucose excretion, patients may experience weight loss in a short period of time, which is particularly beneficial for patients who are obese due to diabetes. Second, empagliflozin has a blood pressure-lowering effect. Studies have shown that patients using empagliflozin may experience a significant reduction in blood pressure, which is an additional health benefit for people with type 2 diabetes, especially those with hypertension. Empagliflozin has also shown cardioprotective effects. Clinical studies have shown that it can reduce the risk of cardiovascular disease in people with type 2 diabetes. This is especially important for people with diabetes because they are generally at higher risk for cardiovascular disease. Empagliflozin may reduce cardiovascular mortality by improving heart function and reducing the risk of heart attack and stroke.
Our professional sales team are waiting for your consultation.
